175 related articles for article (PubMed ID: 31099166)
1. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
[TBL] [Abstract][Full Text] [Related]
2. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
3. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
5. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
6. Entinostat: a promising treatment option for patients with advanced breast cancer.
Connolly RM; Rudek MA; Piekarz R
Future Oncol; 2017 Jun; 13(13):1137-1148. PubMed ID: 28326839
[TBL] [Abstract][Full Text] [Related]
7. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
8. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
9. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
10. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
12. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
13. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
[TBL] [Abstract][Full Text] [Related]
14. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.
Bandyopadhyay A; Favours E; Phelps DA; Pozo VD; Ghilu S; Kurmashev D; Michalek J; Trevino A; Guttridge D; London C; Hirotani K; Zhang L; Kurmasheva RT; Houghton PJ
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29080385
[TBL] [Abstract][Full Text] [Related]
17. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
18. Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner.
Li H; Xu X; Zhang Y; Tang X; Li W
Eur J Pharmacol; 2020 Dec; 888():173575. PubMed ID: 32950498
[TBL] [Abstract][Full Text] [Related]
19. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
